← All trials
NCT07021066
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 30, 2025
- Primary completion
- Feb 28, 2027
- Completion date
- May 31, 2027
- First posted
- Jun 13, 2025
- Last posted
- Nov 20, 2025
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- SystImmune Inc.Lead sponsor
- SystImmune Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.